Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 11/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | TDO2 | P48775 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21835089 | 0.92 | IDO1 (0.55) | IDO1CYP2C9TDO2CYP3A4CYP2C8 | |
| SCHEMBL21835128 | 0.90 | MGLL (0.44) | IDO1CYP2C9TDO2CYP3A4CYP2C8 | |
| SCHEMBL30444706 | 0.90 | MGLL (0.44) | IDO1CYP2C9TDO2CYP3A4CYP2C8 | |
| SCHEMBL23699116 | 0.90 | IDO1 (0.44) | IDO1CYP2C9TDO2CYP3A4CYP2C8 | |
| SCHEMBL21835086 | 0.88 | CHRM4 (0.44) | IDO1CYP2C9TDO2CYP3A4CYP2C8 | |
| SCHEMBL30444001 | 0.88 | CHRM4 (0.44) | IDO1CYP2C9TDO2CYP3A4CYP2C8 | |
| SCHEMBL17740951 | 0.86 | PDGFRB (0.49) | IDO1CYP2C9TDO2CYP3A4CYP2C8 | |
| SCHEMBL21835125 | 0.82 | CHRM4 (0.45) | IDO1CYP2C9TDO2CYP3A4CYP2C8 | |
| SCHEMBL23707438 | 0.82 | CHRM4 (0.48) | IDO1CYP2C9TDO2CYP3A4CYP2C8 | |
| SCHEMBL19093132 | 0.81 | IDO1 (0.51) | IDO1CYP2C9TDO2CYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551478-B2 | Quinoline derivative having indoleamine-2,3-dioxygenase inhibitory activity | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| CN-116574105-A | Quinoline derivatives having indoleamine-2, 3-dioxygenase inhibitory activity | 深圳微芯生物科技股份有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-110950842-B | Quinoline derivatives having indoleamine-2, 3-dioxygenase inhibitory activity | 深圳微芯生物科技股份有限公司 | 2023-06-20 | — | — | CN | disclosed |
| US-20210379052-A1 | QUINOLINE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITORY ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2021-12-09 | — | — | US | disclosed |
| US-20210379052-A1 | QUINOLINE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITORY ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2021-12-09 | — | — | US | disclosed |
| EP-3858813-A1 | QUINOLONE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858813-A1 | QUINOLONE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551478-B2 | Quinoline derivative having indoleamine-2,3-dioxygenase inhibitory activity | IDO2, IDO1, HDAC2 | IDO1 2/4885CYP2C9 715/4885TDO2 16/4885 |
| US-20210379052-A1 | QUINOLINE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITORY ACTIVITY | IDO1, IDO2, INMT | IDO1 1/4885CYP2C9 1821/4885TDO2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.